Contact

Getting Better Drugs to Patients Faster

Methodical target validation, focused drug design & Data-driven translational research
See How

About 1200 Pharma

1200 Pharma was launched in 2017 by a team of world-renowned chemistry and translational oncology researchers from Caltech and UCLA. We leverage breakthrough medicinal chemistry technology, cutting edge computational design, and data-driven biological research to accelerate drug discovery and deliver the right medicines to the right patients.

Accelerating Drug Discovery with Key Expertise and Tools

Success Begins with Target Evaluation and Validation
  • We leverage proprietary genomic, transcriptomic, and protein expression datasets from over 500 human cancer cell lines to identify bona fide therapeutic targets.
  • Targets are interrogated by chemical and genetic methods to elucidate cancer-specific dependencies.
  • Our in vitro and in vivo biology platforms enable the early assessment of drug efficacy and tolerability of multiple therapeutic modalities.
Translationally Focused, Data-Driven Research
  • We are focused on clinical translation and unmet medical need.
  • Rich datasets enable bioinformatic analyses to pinpoint molecular signatures of drug sensitivity and resistance, patient selection biomarkers, and drug combination strategies.
Cutting Edge Chemistry & Drug Design
  • We use proprietary chemistry technology to accelerate drug discovery and drug optimization by mining underexplored, three dimensionally-rich chemical space.
  • Integrated quantum chemistry and computational modeling drive high-value hypotheses and speed the discovery of potent and selective therapeutics.
  • Rigorous use of hypothesis-driven, structure-based drug design rapidly drives discovery toward the best molecule for the desired application.
Success Begins with Target Evaluation and Validation
  • We leverage proprietary genomic, transcriptomic, and protein expression datasets from over 500 human cancer cell lines to identify bona fide therapeutic targets.
  • Targets are interrogated by chemical and genetic methods to elucidate cancer-specific dependencies.
  • Our in vitro and in vivo biology platforms enable the early assessment of drug efficacy and tolerability of multiple therapeutic modalities.
Translationally Focused, Data-Driven Research
  • We are focused on clinical translation and unmet medical need.
  • Rich datasets enable bioinformatic analyses to pinpoint molecular signatures of drug sensitivity and resistance, patient selection biomarkers, and drug combination strategies.
Cutting Edge Chemistry & Drug Design
  • We use proprietary chemistry technology to accelerate drug discovery and drug optimization by mining underexplored, three dimensionally-rich chemical space.
  • Integrated quantum chemistry and computational modeling drive high-value hypotheses and speed the discovery of potent and selective therapeutics.
  • Rigorous use of hypothesis-driven, structure-based drug design rapidly drives discovery toward the best molecule for the desired application.

Our strategic partnership with a world-renowned oncology research center emboldens our target discovery approach

Discover and test cancer dependencies using an extensive and diverse cell line panel
Expertise with models of nearly any human cancer
Our experimental medicines target key vulnerabilities of specific cancers
Our proprietary chemistry allows rapid discovery and development of novel small molecule inhibitors

The Right Drug for the Right Patient & Worldwide Patient Access

We are developing medicines tailored to specific cancers by analyzing hundreds of cancer cell lines to pinpoint molecular and genetic signatures of treatment sensitivity and resistance. Biomarkers allow us to develop companion diagnostic tests to match patients with the right treatment.
Collaborations with expert clinicians and strategic partnerships with global clinical research networks ensure a streamlined path to bring investigational medicines to patients in need. We are partnered with clinical research organizations TRIO-US and TRIO Global to rapidly identify and accrue patients to clinical trials around the world.

Development Pipeline

Lead Optimization
IND Application
Phase 1
Phase 2
Target
ERK1/2
Stage
Phase 1 initiated March 2021, actively recruiting (NCT04761601)
Indication
Mutated Cancers

In multiple preclinical models, including patient-derived xenografts, UCT-01-097 showed strong anti-tumor effects in a broad range of cancer types. See our AACR Annual Meeting Poster Presentation here.

Target
CDK4/6
Stage
Phase 1 initiated December 2021, actively recruiting (NCT05103046)
Indication
Select Non-Small Cell Lung Cancers

UCT-03-008 is a next-generation, long half-life CDK4/6 inhibitor that arrests cell cycle progression and elicits durable anti-tumor effects in multiple preclinical models. See our AACR Annual Meeting Poster Presentation here.

Target
PRMT5
Stage
IND filing expected Q4 2023
Indication
Select Solid Tumors

UCT-000445 is a SAM-competitive PRMT5 inhibitor with class leading specificity, potency, and target residence time. UCT-000445 elicits strong anti-tumor effects in multiple pre-clinical models. See our AACR Annual Meeting Poster Presentation here.

Target
KRASG12C
Stage
IND filing expected Q4 2023
Indication
KRASG12C-Mutated Tumors

UCT-001024 is a highly potent and selective covalent KRASG12C inhibitor that shows broad anti-tumor effects in pre-clinical models. This molecule is being developed for combination with other 1200 Pharma assets. See our AACR Annual Meeting Poster Presentation here.

Target
MCL1
Stage
Preclinical
Indication
Select Solid Tumors

Novel small molecule protein MCL1 inhibitor that displays potent anti-tumor effects in preclinical models of multiple myeloma, leukemia, lymphoma, and select solid tumors as a single agent and in combination with other therapies.

Target
Oncology Target
Stage
Discovery
Indication
Mutant Solid Tumors

Novel small molecule inhibitor that targets an oncogenic protein.

Phase 1
Target
ERK1/2
Stage
Phase 1 initiated March 2021, actively recruiting (NCT04761601)
Indication
Mutated Cancers

In multiple preclinical models, including patient-derived xenografts, UCT-01-097 showed strong anti-tumor effects in a broad range of cancer types. See our AACR Annual Meeting Poster Presentation here.

Phase 1
Target
CDK4/6
Stage
Phase 1 initiated December 2021, actively recruiting (NCT05103046)
Indication
Select Non-Small Cell Lung Cancers

UCT-03-008 is a next-generation, long half-life CDK4/6 inhibitor that arrests cell cycle progression and elicits durable anti-tumor effects in multiple preclinical models. See our AACR Annual Meeting Poster Presentation here.

IND Application
Target
PRMT5
Stage
IND filing expected Q4 2023
Indication
Select Solid Tumors

UCT-000445 is a SAM-competitive PRMT5 inhibitor with class leading specificity, potency, and target residence time. UCT-000445 elicits strong anti-tumor effects in multiple pre-clinical models. See our AACR Annual Meeting Poster Presentation here.

IND Application
Target
KRASG12C
Stage
IND filing expected Q4 2023
Indication
KRASG12C-Mutated Tumors

UCT-001024 is a highly potent and selective covalent KRASG12C inhibitor that shows broad anti-tumor effects in pre-clinical models. This molecule is being developed for combination with other 1200 Pharma assets. See our AACR Annual Meeting Poster Presentation here.

Lead Optimization
Target
MCL1
Stage
Preclinical
Indication
Select Solid Tumors

Novel small molecule protein MCL1 inhibitor that displays potent anti-tumor effects in preclinical models of multiple myeloma, leukemia, lymphoma, and select solid tumors as a single agent and in combination with other therapies.

Lead Optimization
Target
Oncology Target
Stage
Discovery
Indication
Mutant Solid Tumors

Novel small molecule inhibitor that targets an oncogenic protein.

News & Publications